These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16932368)

  • 1. Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients?
    Besarab A; Soman S
    Nat Clin Pract Nephrol; 2005 Dec; 1(2):70-1. PubMed ID: 16932368
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.
    Berweck S; Hennig L; Sternberg C; Dingerkus H; Ludat K; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S80-5. PubMed ID: 10746811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Left ventricular hypertrophy in patients on hemodialysis: importance of anemia].
    Stojimirović B; Petrović D; Obrenović R
    Med Pregl; 2007; 60 Suppl 2():155-9. PubMed ID: 18928184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is regression of left ventricular hypertrophy in maintenance hemodialysis patients possible?
    Bossola M; Tazza L; Vulpio C; Luciani G
    Semin Dial; 2008; 21(5):422-30. PubMed ID: 18764802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anemia in predialysis chronic renal failure: what are we treating?
    Foley RN; Parfrey PS
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S82-4. PubMed ID: 11443774
    [No Abstract]   [Full Text] [Related]  

  • 6. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study.
    Ritz E; Laville M; Bilous RW; O'Donoghue D; Scherhag A; Burger U; de Alvaro F;
    Am J Kidney Dis; 2007 Feb; 49(2):194-207. PubMed ID: 17261422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The heart of the matter - cardiac adequacy in hemodialysis.
    Schiller B; Moran J
    Semin Dial; 2011; 24(3):286-7. PubMed ID: 21564302
    [No Abstract]   [Full Text] [Related]  

  • 8. Anemia and the heart in chronic kidney disease.
    Zalunardo N; Levin A
    Semin Nephrol; 2006 Jul; 26(4):290-5. PubMed ID: 16949467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia and cardiovascular risk in the patient with kidney disease.
    Fishbane S
    Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Erten Y; Ebinç FA; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(6):617-23. PubMed ID: 18661412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular hypertrophy in renal failure a review.
    Arodiwe EB
    Niger J Clin Pract; 2007 Mar; 10(1):83-90. PubMed ID: 17668722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Favourable effects of the treatment of renal anemia in early stage chronic renal failure].
    Kes P
    Lijec Vjesn; 2002; 124(3-4):108-9. PubMed ID: 18956830
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiac disease in the dialysis patient: good, better, best clinical practice.
    Hampl H; Riedel E
    Blood Purif; 2009; 27(1):99-113. PubMed ID: 19169026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of ischemic heart disease in patients with chronic kidney failure].
    Diadyk AI; Bagriĭ AE; Stulikova EL
    Lik Sprava; 1998 Jun; (4):42-5. PubMed ID: 9784699
    [No Abstract]   [Full Text] [Related]  

  • 16. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis.
    Kayikcioglu M; Tumuklu M; Ozkahya M; Ozdogan O; Asci G; Duman S; Toz H; Can LH; Basci A; Ok E
    Nephrol Dial Transplant; 2009 Mar; 24(3):956-62. PubMed ID: 19004849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dialysis performance measures.
    Wolfe RA; Port FK
    Am J Kidney Dis; 2008 May; 51(5):867-8; author reply 868-9. PubMed ID: 18436103
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumorlysis by dialysis.
    Al-Abadi AM; Al-Harbi AS; Al-Mohaya SA; Kechrid M; Azhari O; Shetia S
    Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):589-95. PubMed ID: 17186701
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
    Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
    Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge of sudden death in dialysis patients.
    Ritz E; Wanner C
    Clin J Am Soc Nephrol; 2008 May; 3(3):920-9. PubMed ID: 18372318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.